Literature DB >> 19576287

Altered neurometabolites and motor integration in children exposed to methamphetamine in utero.

L Chang1, C Cloak, C S Jiang, S Farnham, B Tokeshi, S Buchthal, B Hedemark, L M Smith, T Ernst.   

Abstract

Methamphetamine (METH) is a neurotoxic drug. This study aimed to evaluate brain metabolite levels and cognitive function in young children with prenatal METH exposure. 101 children ages 3-4 years were evaluated with neuropsychological tests and underwent proton magnetic resonance spectroscopy ((1)H-MRS) without sedation. Complete datasets from 49 METH-exposed and 49 controls who completed the neuropsychological test battery, and 38 METH-exposed and 37 controls with high-quality MR spectra are reported here. Despite similar physical characteristics (including head circumference), global cognitive function (on Stanford-Binet), parental education, intelligence, mood, and socioeconomic status, METH-exposed children had higher total creatine (tCr: +7%, p=0.003), N-acetyl compounds (NA: +4.3%, p=0.004) and glutamate+glutamine (GLX: +9.6%, p=0.02) concentrations in the frontal white matter, but lower myoinositol (MI: -7%, p=0.01) and MI/tCr (-7.5%, p=0.03) in the thalamus, than control children. The higher frontal white matter NA in the METH-exposed children was due to the higher NA in the METH-exposed girls (+10.2%, p=0.003), but not the boys (+0.8%) compared to sex-matched controls. Furthermore, the METH-exposed children had poorer performance on a visual motor integration (VMI) task, which correlated with lower MI in the thalamus (r=0.26, p=0.03). The higher NA, tCr and GLX concentrations suggest higher neuronal density or cellular compactness in the white matter, especially in the girls, whereas the lower MI suggests lower glial content in the thalamus of these METH-expose children. These findings combined with their poorer performance on VMI also suggest accelerated but aberrant neuronal and glial development in these brain regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576287      PMCID: PMC3142567          DOI: 10.1016/j.neuroimage.2009.06.062

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  37 in total

1.  Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities.

Authors:  Linda Chang; Thomas Ernst; Oliver Speck; Charles S Grob
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

2.  Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure.

Authors:  Linda Chang; Lynne M Smith; Christine LoPresti; M Lynn Yonekura; Jennifer Kuo; Irwin Walot; Thomas Ernst
Journal:  Psychiatry Res       Date:  2004-12-15       Impact factor: 3.222

3.  Magnetic resonance imaging and spectroscopy in fetal ethanol exposed Macaca nemestrina.

Authors:  S J Astley; E Weinberger; D W Shaw; T L Richards; S K Clarren
Journal:  Neurotoxicol Teratol       Date:  1995 Sep-Oct       Impact factor: 3.763

4.  Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study.

Authors:  Thomas E Nordahl; Ruth Salo; Yutaka Natsuaki; Gantt P Galloway; Christy Waters; Charles D Moore; Shawn Kile; Michael H Buonocore
Journal:  Arch Gen Psychiatry       Date:  2005-04

5.  Effects of methamphetamine dependence and HIV infection on cerebral morphology.

Authors:  Terry L Jernigan; Anthony C Gamst; Sarah L Archibald; Christine Fennema-Notestine; Monica Rivera Mindt; Thomas D Marcotte; Thomas L Marcotte; Robert K Heaton; Ronald J Ellis; Igor Grant
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

6.  Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey.

Authors:  W P Melega; M J Raleigh; D B Stout; G Lacan; S C Huang; M E Phelps
Journal:  Brain Res       Date:  1997-08-22       Impact factor: 3.252

7.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.

Authors:  A Brand; C Richter-Landsberg; D Leibfritz
Journal:  Dev Neurosci       Date:  1993       Impact factor: 2.984

8.  Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy.

Authors:  R Kreis; T Ernst; B D Ross
Journal:  Magn Reson Med       Date:  1993-10       Impact factor: 4.668

9.  Structural abnormalities in the brains of human subjects who use methamphetamine.

Authors:  Paul M Thompson; Kiralee M Hayashi; Sara L Simon; Jennifer A Geaga; Michael S Hong; Yihong Sui; Jessica Y Lee; Arthur W Toga; Walter Ling; Edythe D London
Journal:  J Neurosci       Date:  2004-06-30       Impact factor: 6.167

10.  Why is parkinsonism not a feature of human methamphetamine users?

Authors:  Anna Moszczynska; Paul Fitzmaurice; Lee Ang; Kathryn S Kalasinsky; Gregory A Schmunk; Frank J Peretti; Sally S Aiken; Dennis J Wickham; Stephen J Kish
Journal:  Brain       Date:  2003-11-25       Impact factor: 13.501

View more
  41 in total

1.  Differentiating prenatal exposure to methamphetamine and alcohol versus alcohol and not methamphetamine using tensor-based brain morphometry and discriminant analysis.

Authors:  Elizabeth R Sowell; Alex D Leow; Susan Y Bookheimer; Lynne M Smith; Mary J O'Connor; Eric Kan; Carly Rosso; Suzanne Houston; Ivo D Dinov; Paul M Thompson
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

2.  Abnormal brain activation during working memory in children with prenatal exposure to drugs of abuse: the effects of methamphetamine, alcohol, and polydrug exposure.

Authors:  Florence F Roussotte; Jennifer E Bramen; S Christopher Nunez; Lorna C Quandt; Lynne Smith; Mary J O'Connor; Susan Y Bookheimer; Elizabeth R Sowell
Journal:  Neuroimage       Date:  2010-10-30       Impact factor: 6.556

3.  Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice.

Authors:  Jessica A Siegel; Michael J Craytor; Jacob Raber
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

Review 4.  Effects of prenatal methamphetamine exposure: a review of cognitive and neuroimaging studies.

Authors:  Maja A Kwiatkowski; Annerine Roos; Dan J Stein; Kevin G F Thomas; Kirsty Donald
Journal:  Metab Brain Dis       Date:  2013-12-28       Impact factor: 3.584

5.  Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years.

Authors:  Trecia A Wouldes; Linda L Lagasse; Marilyn A Huestis; Sheri Dellagrotta; Lynne M Dansereau; Barry M Lester
Journal:  Neurotoxicol Teratol       Date:  2014-02-22       Impact factor: 3.763

6.  Prenatal methamphetamine exposure and inhibitory control among young school-age children.

Authors:  Chris Derauf; Linda L Lagasse; Lynne M Smith; Elana Newman; Rizwan Shah; Charles R Neal; Amelia M Arria; Marilyn A Huestis; Sheri Dellagrotta; Lynne M Dansereau; Hai Lin; Barry M Lester
Journal:  J Pediatr       Date:  2012-03-15       Impact factor: 4.406

Review 7.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

Review 8.  Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women.

Authors:  Marcela C Smid; Torri D Metz; Adam J Gordon
Journal:  Clin Obstet Gynecol       Date:  2019-03       Impact factor: 2.190

9.  Examining the relationships between prenatal methamphetamine exposure, early adversity, and child neurobehavioral disinhibition.

Authors:  Beau Abar; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Lynne M Smith; Amelia Arria; Marilyn Huestis; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester
Journal:  Psychol Addict Behav       Date:  2012-10-15

Review 10.  Structural, metabolic, and functional brain abnormalities as a result of prenatal exposure to drugs of abuse: evidence from neuroimaging.

Authors:  Florence Roussotte; Lindsay Soderberg; Elizabeth Sowell
Journal:  Neuropsychol Rev       Date:  2010-10-28       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.